source
- Alphabet’s GV tops biotech corporate investors with $5.23 billion in deals since 2025Alphabet’s venture arm GV has become the largest corporate spender in biotech, investing a cumulative $5.23 billion across 20 deals since the start of 2025. The total outlay exceeds the combined v…
- FDA approves prostate cancer and Crohn’s disease therapies as judge rejects effort to block Lilly weight‑loss adsThe U.S. Food and Drug Administration announced approvals for new treatments targeting prostate cancer and Crohn’s disease. The decisions expand therapeutic options for patients with these conditio…